Yuichi Hori et al.

Motugivatrep (SJP-0132) 0.3% Ophthalmic Suspension for Dry Eye Disease: A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Trial

Clinical Ophthalmology, September 2026, 20:1-17
DOI: 10.2147/OPTH.S615529